CJC-1295 research: the measurements

Basal GH, mean GH and IGF-1

The pulse study in healthy men aged 20-40 reported approximately 7.5-fold higher basal GH one week after CJC-1295. Mean GH rose by about 46%; IGF-1 rose by about 45%. Pulse frequency and magnitude were unaltered. These are separate measurements from the same study, so the large basal figure can sit quite honestly beside the smaller percentage changes.

I expected a dramatic number from the pulse measurements. Instead, the intervening level did. That distinction stops me using “more GH” as though it described a single change. A preserved rhythm says something about secretion; a raised baseline says something else about the exposure between bursts.

The men received a single study administration. Their amounts appear on the dosage page. The experiment investigated hormone secretion in healthy volunteers, leaving clinical benefit and lasting safety unsettled.

Hormones over several days

Teichman and colleagues studied healthy adults aged 21-61. They reported dose-dependent 2- to 10-fold increases in mean plasma GH for 6 days or more, with 1.5- to 3-fold increases in IGF-1 for 9-11 days. After multiple study doses, IGF-1 remained above baseline up to 28 days. Estimated CJC-1295 half-life was 5.8-8.1 days.

Those figures describe different clocks. Half-life concerns the peptide’s disappearance; the GH and IGF-1 findings concern the hormonal response. Collapsing these clocks into a single claim about how long CJC-1295 “works” would obscure which measurement lasted. In particular, the 28-day observation followed multiple doses. It cannot be presented as the result of one administration.

Serum proteins

The later serum-protein study in 11 healthy young men found decreases in apolipoprotein A1 and a transthyretin isoform, alongside increases in an albumin fragment and immunoglobulin/beta-hemoglobin species. The immunoglobulin and albumin-fragment signal correlated with IGF-1. The investigators were identifying candidate markers of GH/IGF-1 activity.

That precise laboratory question suits my curiosity. Once hormone stimulation is established, the next laboratory question can be where else it leaves a trace. A changed serum protein profile records a biological response; the study did not establish that those changes improved health.

Rat and mouse experiments

In the rat and laboratory stability experiments, the albumin-binding design produced a 4-fold increase in GH area under the curve over 2 hours compared with unconjugated hGRF(1-29). Area under the curve adds up exposure over the measured period. Peptide remained detectable beyond 72 hours, and the stability tests examined resistance to enzymatic breakdown outside the body.

A separate experiment used mice unable to make GHRH. CJC-1295 restored normal body weight and length under the most frequent tested regimen; wider intervals were less effective. The missing natural hormone gives that experiment its force. Its success addresses a particular deficiency in specially bred mice, whereas the human pulse study involved healthy men.

CJC-1295 and ipamorelin

The rationale for pairing the two peptides starts with different receptors: CJC-1295 acts at the GHRH receptor, while ipamorelin acts through the ghrelin/GHS receptor. The review of GHRH and its analogues supplies the broader pharmacological context. A larger release of GH is a mechanistic possibility, and that helps explain the interest in the combination.

The clinical case for the specific pairing remains thin. Controlled human efficacy trials have not established its claimed benefits, and there is no validated human combination dose. I’m wary of borrowing certainty from CJC-1295’s single-substance hormone studies to describe a combination they never tested.

The same review discusses sermorelin and tesamorelin. Tesamorelin has approval for HIV-associated abnormal fat accumulation. Each compound has its own clinical record; CJC-1295 remains unapproved.